AGEN - Agenus Inc.
| Previous Close | 3.8300 |
| Open | 3.8400 |
| Bid | 3.8100 x 3100 |
| Ask | 4.0200 x 1100 |
| Day's Range | 3.7500 - 3.8700 |
| 52 Week Range | 1.9500 - 4.5700 |
| Volume | 568,930 |
| Avg. Volume | 1,159,834 |
| Market Cap | 527M |
| Beta (5Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9620 |
| Earnings Date | Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Thomson Reuters StreetEvents
Edited Transcript of AGEN earnings conference call or presentation 4-Nov-19 1:30pm GMT
Q3 2019 Agenus Inc Earnings Call
- Zacks
Agenus (AGEN) Up 24.5% Since Last Earnings Report: Can It Continue?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
- Zacks
Moving Average Crossover Alert: Agenus
Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.
- PR Newswire
Agenus to Host R&D Day November 15, 2019
LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, ...
- Zacks
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- PR Newswire
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with UroGen Pharma Ltd. Under the agreement Agenus is providing access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with UroGen's sustained release technology for intravesical delivery in patients with urinary tract cancers. Agenus is conducting clinical trials for zalifrelimab in combination with Agenus' anti-PD-1 antibody balstilimab (AGEN2034) for a planned BLA filing in cervical cancer.
- Zacks
Will Agenus Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Agenus.
- Benzinga
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...
- Zacks
Are You Looking for a Top Momentum Pick? Why Agenus (AGEN) is a Great Choice
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Insider Monkey
Hedge Funds Have Never Been Less Bullish On Agenus Inc (AGEN)
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
- Zacks
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
- Zacks
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 13.16% and 27.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Agenus Provides Corporate Update with Third Quarter 2019 Financial Results
- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies ...
- PR Newswire
Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and provide a business update. The call will also be webcast and will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/31794.
- Zacks
Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Does Agenus Inc.'s (NASDAQ:AGEN) CEO Pay Matter?
Garo Armen became the CEO of Agenus Inc. (NASDAQ:AGEN) in 1994. This report will, first, examine the CEO compensation...
- Market Realist
Agenus: Attractive Entry Level after Recent Pullback
This year, Agenus (AGEN) stock has fluctuated widely. The clinical-stage biotechnology company's stock fell from $3.88 in February to about $2.12 in August.
- PR Newswire
Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, ...
- Zacks
Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Before You Buy Agenus Inc. (NASDAQ:AGEN), Consider Its Volatility
If you own shares in Agenus Inc. (NASDAQ:AGEN) then it's worth thinking about how it contributes to the volatility of...
- Thomson Reuters StreetEvents
Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Agenus Inc Earnings Call
